Get Our Top Trade Ideas Delivered Daily - 65% Off Now
get this deal
España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Our Top Trade Ideas Delivered Daily - 65% Off Now
get this deal
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
AbbVie
ABBV
NYSE
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$193.83
0.36
0.19%
At Close: -
$193.83
0
0.00%
After Hours: 4:43 PM EDT
15 minutes delayed
Get Report
Comment
AbbVie (ABBV) Forecast
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Government Trades
Short Interest
Latest news for AbbVie (NYSE:ABBV) Stock
AbbVie Stock (NYSE: ABBV)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, September 20, 2024
Bristol-Myers Acquired Drug KarXT Poised For FDA Approval As First New Type Of Schizophrenia Treatment In 70 Years
Vandana Singh
Spotlight on AbbVie: Analyzing the Surge in Options Activity
Benzinga Insights
CHMP Recommended Granting Marketing Authoriza...
Benzinga Newsdesk
Thursday, September 19, 2024
Competitor Analysis: Evaluating AbbVie And Competitors In Biotechnology Industry
Benzinga Insights
Tuesday, September 17, 2024
Ripple Therapeutics Announces Collaboration A...
Benzinga Newsdesk
TransDigm, BJ's Wholesale, AbbVie And More On CNBC's 'Final Trades'
Avi Kapoor
Monday, September 16, 2024
CNBC Halftime Report Final Trades: Taiwan Sem...
Benzinga Newsdesk
Wednesday, September 11, 2024
UnitedHealth Follows Competitors, Replaces Humira with Lower-Cost Biosimilars
Vandana Singh
What the Options Market Tells Us About AbbVie
Benzinga Insights
AbbVie's Allergan Aesthetics Launches BOTOX C...
Benzinga Newsdesk
Tuesday, September 10, 2024
Teva Announces $80M Settlement To Baltimore: City Continues Opioid Litigation Against Other Companies
Vandana Singh
UnitedHealth Group Says It Will Remove AbbVie...
Benzinga Newsdesk
Unitedhealth Says It Will Remove Abbvie's Hum...
Benzinga Newsdesk
AbbVie's CONSTELLA Receives Health Canada App...
Benzinga Newsdesk
Monday, September 09, 2024
Spotlight on AbbVie: Analyzing the Surge in Options Activity
Benzinga Insights
AbbVie To Present New Data From Antibody-Drug...
Benzinga Newsdesk
Friday, September 06, 2024
Peering Into AbbVie's Recent Short Interest
Benzinga Insights
Thursday, September 05, 2024
Psychedelic Drugs Market Set To Grow By $1.37B By 2028, Driven By Mental Health Disorders And AI Integration
Juan Spínelli
Here's How Much $100 Invested In AbbVie 10 Years Ago Would Be Worth Today
Benzinga Insights
Wednesday, September 04, 2024
AbbVie Announces VRAYLAR Receives Reimburseme...
Benzinga Newsdesk
Tuesday, September 03, 2024
10 Health Care Stocks With Whale Alerts In Today's Session
Benzinga Insights
Thursday, August 29, 2024
AbbVie Options Trading: A Deep Dive into Market Sentiment
Benzinga Insights
Wednesday, August 28, 2024
As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors
Vandana Singh
Tuesday, August 27, 2024
Regulators Expected To Approve Innovative Schizophrenia Treatment From Bristol Myers, Karuna
Anthony Noto
Monday, August 26, 2024
AbbVie Unusual Options Activity For August 26
Benzinga Insights
Friday, August 23, 2024
Novo Nordisk's Ozempic Might Be Among 2027 Medicare Price Negotiation Targets
Vandana Singh
Key Takeaways From AbbVie Analyst Ratings
Benzinga Insights
Piper Sandler Maintains Overweight on AbbVie,...
Benzinga Newsdesk
Tuesday, August 20, 2024
Unpacking the Latest Options Trading Trends in AbbVie
Benzinga Insights
$100 Invested In This Stock 10 Years Ago Would Be Worth $400 Today
Benzinga Insights
Monday, August 19, 2024
Genmab A/S Announces TEPKINLY Has Received Se...
Benzinga Newsdesk
Thursday, August 15, 2024
10 Health Care Stocks With Whale Alerts In Today's Session
Benzinga Insights
AbbVie Announces EPKINLY Listing On Ontario H...
Benzinga Newsdesk
Wednesday, August 14, 2024
Decoding AbbVie's Options Activity: What's the Big Picture?
Benzinga Insights
Tuesday, August 13, 2024
3 Big Drug Stocks to Watch on Raised 2024 Earnings & Sales View
Zacks
Cancer-Focused Syros Pharmaceuticals Stops Mid-Stage Leukemia Combo Therapy Study, Cites Disappointing Unexpected Outcome
Vandana Singh
Monday, August 12, 2024
Morgan Stanley Maintains Overweight on AbbVie...
Benzinga Newsdesk
Botox Innovator Revance Therapeutics Goes Private In Over $900M Deal
Vandana Singh
Friday, August 09, 2024
Ironwood Q2 Earnings & Revenues Fall Shy of Estimates
Zacks
Wednesday, August 07, 2024
Warren Buffett's Approach To Investing In Election Years
Aaron Bry
Tuesday, August 06, 2024
AbbVie, Leidos, KKR And More On CNBC's 'Final Trades'
Avi Kapoor
Monday, August 05, 2024
Cantor Fitzgerald Reiterates Overweight on Ab...
Benzinga Newsdesk
CNBC Halftime Report Final Trades: KKR & Co.,...
Benzinga Newsdesk
Friday, August 02, 2024
Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years
Benzinga Insights
Thursday, August 01, 2024
8 Health Care Stocks With Whale Alerts In Today's Session
Benzinga Insights
CNBC Halftime Report Final Trades: Amazon.com...
Benzinga Newsdesk
Wednesday, July 31, 2024
A Closer Look at AbbVie's Options Market Dynamics
Benzinga Insights
Tuesday, July 30, 2024
Bristol Myers, Johnson & Johnson, AbbVie, AstraZeneca Expect Minimal Impact From Upcoming Medicare Price Negotiations
Vandana Singh
Friday, July 26, 2024
AbbVie Wins Analyst Confidence with Q2 Beat, Diverse Portfolio Fuels Long-Term Growth Expectations
Vandana Singh
Cantor Fitzgerald Reiterates Overweight on Ab...
Benzinga Newsdesk
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch
